Biotech & Genomic Medicine▲
Kyungdong Pharmaceutical and Asimov complete cell line development for biosimilar antibody
Kyungdong Pharmaceutical and Asimov have completed a cell line development campaign for a biosimilar antibody candidate. Kyungdong secured a high-performing production cell line using Asimov's CHO Edge System, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library, and the AI-driven genetic design software Kernel. The resulting cell line achieved a high titer, supporting downstream process development and future commercialization. Kyungdong CEO Ryu Gi-sung expressed satisfaction with the collaboration as the company expands its biopharmaceutical business.
About megatrends
Biotech & Genomic Medicine › Biosimilars Technology
011040.KQ · Technology · Positive Completed cell line development for biosimilar antibody using Asimov's system, advancing its biopharmaceutical pipeline.
Asimov · Technology · Positive Successfully applied its CHO Edge System and Kernel software in a collaboration, validating its technology platform.